Karen J. Scott

University of Leeds — United Kingdom

Biochemistry, Genetics and Molecular Biology · Life Sciences

24h-index2.2kcitations76works0.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Virus-based gene therapy research(41), Cancer Research and Treatments(23), CAR-T cell therapy research(17), Hepatocellular Carcinoma Treatment and Prognosis(14), Nanoplatforms for cancer theranostics(14)

Publications76 total

Single versus repeated intravenous oncolytic reovirus infusions: Implications for immune modulation and rationalised scheduling of therapy in hepatocellular carcinoma
International Journal of Cancer·2026Open Access
POSTERIOR SCLERITIS AND OCULAR SARCOIDOSIS UNMASKING HETEROZYGOUS CYTOTOXIC T LYMPHOCYTE-ASSOCIATED ANTIGEN CTLA-4 HAPLOINSUFFICIENCY
Annals of Allergy Asthma & Immunology·2025
The immune and genetic heterogeneity of hepatocellular carcinoma, with a focus on multifocal disease
2025Open Access
Figure 2 from A Phase I Clinical Trial of Intrahepatic Artery Delivery of TG6002 in Combination with Oral 5-Fluorocytosine in Patients with Liver-Dominant Metastatic Colorectal Cancer
2025Open Access
Figure 5 from A Phase I Clinical Trial of Intrahepatic Artery Delivery of TG6002 in Combination with Oral 5-Fluorocytosine in Patients with Liver-Dominant Metastatic Colorectal Cancer
2025Open Access
Supplementary Table S3 from A Phase I Clinical Trial of Intrahepatic Artery Delivery of TG6002 in Combination with Oral 5-Fluorocytosine in Patients with Liver-Dominant Metastatic Colorectal Cancer
2025Open Access
Figure 4 from A Phase I Clinical Trial of Intrahepatic Artery Delivery of TG6002 in Combination with Oral 5-Fluorocytosine in Patients with Liver-Dominant Metastatic Colorectal Cancer
2025Open Access
Supplementary Table S2 from A Phase I Clinical Trial of Intrahepatic Artery Delivery of TG6002 in Combination with Oral 5-Fluorocytosine in Patients with Liver-Dominant Metastatic Colorectal Cancer
2025Open Access
Supplementary Figure S1 from A Phase I Clinical Trial of Intrahepatic Artery Delivery of TG6002 in Combination with Oral 5-Fluorocytosine in Patients with Liver-Dominant Metastatic Colorectal Cancer
2025Open Access
Table 1 from A Phase I Clinical Trial of Intrahepatic Artery Delivery of TG6002 in Combination with Oral 5-Fluorocytosine in Patients with Liver-Dominant Metastatic Colorectal Cancer
2025Open Access
Table 2 from A Phase I Clinical Trial of Intrahepatic Artery Delivery of TG6002 in Combination with Oral 5-Fluorocytosine in Patients with Liver-Dominant Metastatic Colorectal Cancer
2025Open Access
Figure 6 from A Phase I Clinical Trial of Intrahepatic Artery Delivery of TG6002 in Combination with Oral 5-Fluorocytosine in Patients with Liver-Dominant Metastatic Colorectal Cancer
2025Open Access
Figure 1 from A Phase I Clinical Trial of Intrahepatic Artery Delivery of TG6002 in Combination with Oral 5-Fluorocytosine in Patients with Liver-Dominant Metastatic Colorectal Cancer
2025Open Access
Data from A Phase I Clinical Trial of Intrahepatic Artery Delivery of TG6002 in Combination with Oral 5-Fluorocytosine in Patients with Liver-Dominant Metastatic Colorectal Cancer
2025Open Access
Figure 3 from A Phase I Clinical Trial of Intrahepatic Artery Delivery of TG6002 in Combination with Oral 5-Fluorocytosine in Patients with Liver-Dominant Metastatic Colorectal Cancer
2025Open Access
Supplementary Table S1 from A Phase I Clinical Trial of Intrahepatic Artery Delivery of TG6002 in Combination with Oral 5-Fluorocytosine in Patients with Liver-Dominant Metastatic Colorectal Cancer
2025Open Access
A Phase I Clinical Trial of Intrahepatic Artery Delivery of TG6002 in Combination with Oral 5-Fluorocytosine in Patients with Liver-Dominant Metastatic Colorectal Cancer
Clinical Cancer Research·2025· 9 citedOpen Access
NA
immuneACCESS·2024
Single versus repeated intravenous oncolytic reovirus infusions: Implications for immune modulation and rationalised scheduling of therapy in hepatocellular carcinoma
2024Open Access
A phase I clinical trial of intrahepatic artery delivery of TG6002 in combination with oral 5-fluorocytosine in patients with liver-dominant metastatic colorectal cancer
2024Open Access
page 1 of 4Next →

Frequent Co-authors

Alan Melcher(44), Emma J. West(27), Adel Samson(18), Richard G. Vile(16), Kevin J. Harrington(15), Fiona Errington‐Mais(14), Christy Ralph(13), Hardev Pandha(13), Peter J. Selby(13), Elizabeth J. Ilett(12), Alan Anthoney(11), Fiona Collinson(9), Susan Short(9), Matt Coffey(9), Giles J. Toogood(9), Ailsa Rose(8), Kaïdre Bendjama(8), Chris Twelves(8), Samantha Turnbull(7), Matthew Coffey(7)